ENTBF News and Press, Entheon Biomedical Corp Com From 01/06/22

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personali...

Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( ...

Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide persona...

Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming trial, EBRX-101 is designed to be one of the most comprehensive studies of DMT to ...

Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Eric Sprott announces that, today, 600,000 common share purchase warrants (Warrants) of Entheon Biomedical Corp., (held by 2176423 Ontario Ltd., a corporation he beneficially owns) expired unexercised representing a decrease in holdings o...

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personal...

Detroit, Michigan--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical (CSE: ENBI) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the gl...

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personal...

Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company f...

Entheon Biomedical (OTCQB:ENTBF) announces that recruitment has begun for the clinical research study with Heading Health to determine the electro-neurophysiologic effects of ketamine. EBIQ-101, an Open Label Observational Study, will observe the EEG pattern of participants being treated...